ImmunityBio (IBRX) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free IBRX Stock Alerts $8.12 +0.06 (+0.74%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImmunityBio (NASDAQ:IBRX) Shares Gap Down to $8.06marketbeat.com - May 10 at 7:28 PMIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024investorplace.com - May 10 at 11:02 AMThe 3 Best Bargain Stocks to Buy in May 2024investorplace.com - May 9 at 6:01 AMLatest News for ImmunityBio Stock (NASDAQ:IBRX)benzinga.com - May 8 at 9:02 PMImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®finance.yahoo.com - May 7 at 7:57 PMImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81marketbeat.com - May 7 at 2:19 PMImmunityBio (NASDAQ:IBRX) Shares Down 12.6% marketbeat.com - May 6 at 8:25 PMEven Worse than Gamestop? 3 Meme Stocks That Are Screaming Sellsinvestorplace.com - May 6 at 6:00 AMSerum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapymsn.com - May 3 at 4:59 PMImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Typesbusinesswire.com - May 2 at 4:04 PMImmunityBio (NASDAQ:IBRX) Trading Up 11.4%marketbeat.com - May 1 at 5:20 PMPromising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising Diagnosestheglobeandmail.com - May 1 at 12:37 PMImmunityBio (NASDAQ:IBRX) Shares Down 6.3% marketbeat.com - April 30 at 5:35 PMImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Associationbusinesswire.com - April 30 at 8:00 AMImmunityBio (NASDAQ:IBRX) Sets New 12-Month High Following Analyst Upgrademarketbeat.com - April 29 at 9:23 AMPiper Sandler Increases ImmunityBio (NASDAQ:IBRX) Price Target to $6.00marketbeat.com - April 29 at 8:06 AMWhat's Going On With ImmunityBio Stock?msn.com - April 26 at 9:59 PMImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volumemarketbeat.com - April 26 at 8:10 PMImmunityBio (NASDAQ:IBRX) Trading 4.6% Higher marketbeat.com - April 25 at 8:44 PMFDA approves local company's bladder cancer drugbizjournals.com - April 25 at 12:17 PMImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancerbusinesswire.com - April 25 at 12:03 AMValidea Detailed Fundamental Analysis - IBRXnasdaq.com - April 24 at 9:14 PMFDA approves bladder cancer treatment by Culver City companymsn.com - April 24 at 4:14 PMFDA Approves ImmunityBio's Bladder Cancer Drug, Stock Ralliesfinance.yahoo.com - April 23 at 7:50 PMImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gainsseekingalpha.com - April 23 at 5:11 PMImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)marketbeat.com - April 23 at 12:30 PMImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battleseekingalpha.com - April 23 at 11:45 AMBiggest stock movers today: IBRX, NVS, and moremsn.com - April 23 at 8:26 AMImmunityBio stock jumps as FDA clears bladder cancer therapymsn.com - April 23 at 8:26 AMImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancerbusinesswire.com - April 22 at 9:56 PMU.S. FDA approves ImmunityBio's bladder cancer therapyreuters.com - April 22 at 6:38 PMImmunityBio (NASDAQ:IBRX) Shares Down 4% marketbeat.com - April 22 at 5:37 PMImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5%marketbeat.com - April 19 at 11:59 AMImmunityBio, Inc. (IBRX) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - April 17 at 1:07 AMVanguard Group Inc. Increases Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)marketbeat.com - April 13 at 4:31 AMImmunityBio (NASDAQ:IBRX) Trading Down 8.1%marketbeat.com - April 12 at 2:51 PMImmunityBio (NASDAQ:IBRX) Shares Up 3.7%marketbeat.com - April 11 at 1:47 PMImmunityBio (NASDAQ:IBRX) Trading Up 8%marketbeat.com - April 3 at 4:51 PMImmunityBio (NASDAQ:IBRX) Shares Down 6.7% marketbeat.com - April 1 at 2:58 PMImmunityBio (NASDAQ:IBRX) Trading Up 6.2%marketbeat.com - March 28 at 7:27 PMAnalysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)markets.businessinsider.com - March 25 at 9:51 PMImmunityBio (NASDAQ:IBRX) Trading Down 5.1%marketbeat.com - March 25 at 4:23 PMPiper Sandler Boosts ImmunityBio (NASDAQ:IBRX) Price Target to $5.00marketbeat.com - March 25 at 8:10 AMImmunityBio (NASDAQ:IBRX) Shares Up 8.6%marketbeat.com - March 22 at 12:06 PMImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volumemarketbeat.com - March 20 at 12:46 PMIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023investorplace.com - March 19 at 11:07 PMImmunityBio: Q4 Earnings Insightsbenzinga.com - March 19 at 7:19 PMImmunityBio, Inc. (NASDAQ:IBRX) Sees Large Increase in Short Interestmarketbeat.com - March 18 at 9:56 PMIBRX Jan 2025 1.500 putfinance.yahoo.com - March 17 at 9:08 AMIBRX Jul 2024 1.000 putfinance.yahoo.com - March 16 at 9:57 AM Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here IBRX Media Mentions By Week IBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.240.55▲Average Medical News Sentiment IBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼103▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HALO News CRSP News RVMD News KRYS News PCVX News IMVT News EXEL News SWTX News IOVA News IMCR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
